IMP321 IND Allowance in Pancreatic Cancer (10/2008)
Immutep S.A. announced today that the FDA, after review of the Investigational New Drug Application (IND), has allowed the administration of IMP321 in cancer patients in a Phase I trial conducted by ... |
LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy (06/2008)
Immutep S.A. announced today the publication of research conducted by Cell Genesys, Inc. showing that a lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage ... |
IMP321 first results in metastatic breast cancer (11/2007)
Immutep S.A announced positive interim results from a Phase I/II study of its lead product, ImmuFact® IMP321 in patients with metastatic breast cancer (MBC). The data were presented at the 22nd ... |
IMP321’s potency as a new immunopotentiator in cancer patients (09/2007)
Immutep Announces That ImmuFact® IMP321 Induces Activation of a Wide Range of Human Effector Cytotoxic Cells.Research paper describes IMP321’s potency as a new immunopotentiator in ... |
Entering Phase I (09/2007)
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I clinical trial in metastatic melanoma in a novel protocol combining adoptive T cell transfer after transient lymphodepletion associated ... |
Entering Phase I (10/2006)
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in MelanomaOrsay, September 25, 2006, lmmutep S.A. announced today that its lead product, ... |
Entering Phase I (08/2006)
Immutep Announces That ImmuFact® IMP321 Has Entered A Phase I Chemoimmunotherapy Trial In Breast Cancer.Orsay, August 3, 2006, Immutep S.A. announced today that its lead product, ImmuFact® ... |
IMMUFACT (05/2006)
Immutep S.A. announces that IMMUFACT® IMP321 has successfully completed Phase I Studies.Immutep S.A. announced today that its lead product, ImmuFact® IMP321, has successfully completed ... |
Soluble LAG-3 (05/2006)
Immutep S.A. announced today the publication of a research paper showing that a soluble human LAG-3 protein amplifies the in vitro generation of type 1 tumor-specific immunity.The study ... |
sLAG-3 (04/2006)
Immutep S.A. announced today the publication of a research paper showing that soluble LAG-3 (Lymphocyte Activation Gene-3) protein (sLAG-3) is a prognostic indicator for survival in breast cancers ... |
Phase I (11/2005)
Immutep S.A. announced today that it has initiated a Phase I clinical trial of its lead product ImmuFact® IMP321 in metastatic renal cell carcinoma. This is the Company's first clinical trial ... |
Michel Gréco (09/2005)
Immutep S.A. announced today the appointment of Michel Gréco to its Board of Directors. Mr. Gréco brings over 30 years of experience of the vaccine and pharmaceutical industry and presently sits on ... |
First clinical trials (04/2005)
Immutep S.A. announced today that its lead product ImmuFact® IMP321 has moved into Phase I/II clinical trials. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to ... |
Second Funding (01/2005)
Immutep S.A. announced today the closing in December of a second financing of €2.5 million ($3.25 million) taking the total amount raised externally by the Company to €5 million ($6.5 million). The ... |
First Funding (04/2004)
IMMUTEP closes funding to develop novel therapeutic vaccines. Click to read the complete Press Release (PDF Format). |
© 2002 Immutep, S.A.
